Evidence map›Paper›PMID 31322277›Full record

ArticleMolecular medicine reports2019

MicroRNA‑let‑7a inhibition inhibits LPS‑induced inflammatory injury of chondrocytes by targeting IL6R.

Cong Sui, Lecheng Zhang, Yong Hu

Abstract read
In one paragraph

Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Protective Potential ofPharmaceuticals (Basel, Switzerland) · 2023
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Crosstalk Among circRNA/lncRNA, miRNA, and mRNA in Osteoarthritis.Frontiers in cell and developmental biology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Cong SuiDepartment of Orthopaedics (Trauma Orthopaedics Ward), The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China.
Lecheng ZhangDepartment of Orthopaedics (Trauma Orthopaedics Ward), The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China.
Yong HuDepartment of Orthopaedics (Trauma Orthopaedics Ward), The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoarthritis (OA) is a type of degenerative joint disease that affects the health of the elderly. OA is characterized by articular cartilage degradation and joint inflammation. The present study aimed to investigate the role and mechanism of microRNA‑let‑7a (Let‑7a) in OA by examining its role in lipopolysaccharide (LPS)‑induced cartilage inflammatory injury in ATDC5 cells. ATDC5 cells were treated with various concentrations of LPS. The present results suggested that 5 and 10 µg/ml LPS significantly inhibited ATDC5 cell viability, and 5 µg/ml LPS was selected for further experiments. Reverse transcription‑quantitative PCR (RT‑qPCR) results suggested that treatment with LPS significantly induced the expression levels of multiple inflammatory factors, including tumor necrosis factor‑α (TNF‑α), interleukin (IL)‑1β, IL‑6 and IL‑8, and increased the expression level of Let‑7a in ATDC5 cells. IL‑6 receptor (IL‑6R) was identified to be a direct target of Let‑7a using TargetScan and a dual‑luciferase reporter assay. Subsequently, Cell Counting Kit‑8 and flow cytometry analyses identified that Let‑7a inhibitor could significantly promote cell viability and reduce cell apoptosis in ATDC5 cells treated with LPS, and these effects could be reversed by transfection with small interfering (si)RNA‑IL‑6R. ELISA was used to examine the expression of inflammatory factors in ATDC5 cells following treatment with LPS. Additionally, RT‑qPCR and western blotting were performed to detect the mRNA and protein expression level of IL‑6R and STAT3. The present results suggested that Let‑7a inhibitor significantly reduced the expression level of TNF‑α, IL‑1β, IL‑6 and IL‑8 in ATDC5 cells, and this effect was reversed by transfecting siRNA‑IL‑6R. Moreover, RT‑qPCR and western blot assay results suggested that Let‑7a inhibitor significantly increased the expression level of IL‑6R and phosphorylated STAT3, and these effects could be reversed by siRNA‑IL‑6R. Collectively, Let‑7a inhibitor increased cell proliferation, reduced apoptosis and inhibited inflammatory response in ATDC5 cells treated with LPS. The present study provided a new potential therapeutic target for OA treatment.

Indexed as

Cell LineCell SurvivalChondrocytesDown-RegulationHumansInflammationLipopolysaccharidesMicroRNAsReceptors, Interleukin-6Up-RegulationIL6R protein, humanLipopolysaccharidesMicroRNAsmirnlet7 microRNA, humanReceptors, Interleukin-6

Identifiers

PMID31322277
PMCPMC6691277

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.